900904 神奇 B 股 证券代码：600613 证券简称：神奇制药 公告编号：2025-009 上海神奇制药投资管理股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 16 日 9 点 30 分 召开地点：贵州省贵阳市观山湖区毕节路 58 号联合广场 1 号楼 37 层会议室 1 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过 ...

| 证券代码：A | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | B | | | | | | | 股 股 | | | | | | | | | | | | 600613 900904 | | | | | | | | | | | | 股票简称：A | | | | | | | | | | | | | | | 神奇制药 神奇 B 股 | | | | | | | | | | | | 编号： | 2025-005 | | | | | | B | | | | | | | | | | | | | 股 股 | | | | 上海神奇制药投资管理股份有限公司 第十一届监事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届监事会 第八次会议通知已于 2025 年 4 月 14 日分别以传真、邮件、短信等方式通知全体 监事。根据《 ...

| | | 上海神奇制药投资管理股份有限公司 第十一届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届董事会 第八次会议通知已于 2025 年 4 月 14 日分别以送达、传真、邮件等方式通知公司 董事、监事。会议于 2025 年 4 月 24 日在贵阳市观山湖区毕节路 58 号联合广场 1 号楼 39 层会议室以现场表决方式召开。应参会董事 9 人，现场参会董事 9 人。 公司监事和部分高管人员列席了会议。会议由公司董事长 ZHANGTAOTAO 先生主持。 会议符合《公司法》及《公司章程》的有关规定，会议及表决合法有效。经审议， 会议通过如下决议： 一、审议通过《公司 2024 年度总经理工作报告》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议通过《公司 2024 年度董事会工作报告》 董事会审议通过了本议案，并同意提交公司 2024 年年度股东大会审议。 三、审议通过《公司 2024 年度报告及报告摘要》 公司董 ...

| 证券代码：A | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | B | | | | | | | | | | | | 股 股 | | | | | | | | | | | | 600613 900904 | 股票简称：A | B | | | | | | | | | | | | 股 股 | | | | | | | | | | | | 神奇制药 神奇 B 股 | | | | | | | | | | | | 编号： | 2025-006 | 上海神奇制药投资管理股份有限公司 关于 2024 年度利润分配方案及提请股东大会授权董 事会制定 2025 年中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 分配比例：每 10 股派发现金红利 1.5 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。 在实施权益分派的股权登记 ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,048,808,450.63, a decrease of 12.48% compared to CNY 2,340,945,518.00 in 2023[23] - The net profit attributable to shareholders for 2024 increased by 25.24% to CNY 71,388,047.35 from CNY 57,000,674.55 in 2023[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 was CNY 71,121,491.20, up 44.84% from CNY 49,103,973.11 in 2023[23] - The net cash flow from operating activities for 2024 was CNY 207,785,516.12, a decrease of 3.62% compared to CNY 215,590,355.95 in 2023[23] - The total assets at the end of 2024 were CNY 3,115,812,628.78, down 4.99% from CNY 3,279,335,678.82 at the end of 2023[23] - The net assets attributable to shareholders at the end of 2024 were CNY 2,363,038,500.50, an increase of 1.18% from CNY 2,335,387,196.13 at the end of 2023[23] - Basic earnings per share increased by 18.18% to CNY 0.13 compared to CNY 0.11 in the same period last year[24] - The weighted average return on equity increased by 0.59 percentage points to 3.01% compared to 2.42% in the previous year[24] Operational Strategy - The company aims to enhance operational control and promote strategic layout amidst rapidly changing industry policies and market conditions[32] - The marketing strategy focuses on maintaining market share while adapting to the evolving healthcare policies and market dynamics[33] - The company is committed to optimizing its organizational structure and enhancing digital applications to support data-driven decision-making[32] - The company aims to enhance the market share of prescription drugs and explore new business models to improve profitability in 2024[35] - In 2024, the company will deepen the refined management of over-the-counter drug marketing, establishing strategic partnerships with over 200 major chain enterprises[36] - The company is focusing on building a professional marketing team, emphasizing talent specialization and management refinement to adapt to market competition and consumer demand[36] - The company is strengthening its commercial control and risk management systems to ensure deep and broad coverage of its products in medical terminals[37] Research and Development - In 2024, the company will continue to upgrade its product strategy and increase R&D efforts, focusing on strong competitive products and evidence-based medicine research[38] - The company has made significant breakthroughs in the industrialization of potential products, which have become new sales growth points[39] - The company is advancing clinical research on its leading oncology products to enhance their core competitive advantages and drive steady sales growth[39] - The company has established a multi-level R&D system and collaborates with major hospitals for clinical research and product development[63] - The company has advanced equipment and facilities for research, development, and pilot production, supporting new drug development and process standard improvements[116] - The company has completed addiction analysis studies for its products, including the safety studies for Sodium Cantharidinate Injection[116] - Major R&D projects included anti-tumor drug research with an investment of 21,418,807.06 RMB, showing a year-on-year increase of 157.10%[126] Market Trends and Challenges - The pharmaceutical manufacturing industry in China is projected to see a revenue decline of 3.7% in 2024, with total revenue expected to reach CNY 25,205.7 billion[48] - The total profit for the pharmaceutical manufacturing sector is forecasted to decrease by 15.1% in 2024, amounting to CNY 3,473.0 billion[48] - The Chinese pharmaceutical market is experiencing a shift, with the market share of chemical generics declining from 60% to 52% due to the rise of innovative drugs[50] - The national drug procurement policy has led to significant savings, with approximately CNY 4.4 trillion saved since 2018, primarily benefiting innovative drug payments[52] - The average price drop for the third batch of national Chinese medicine procurement was 63%, marking a higher reduction compared to previous batches[53] - The pharmaceutical manufacturing industry is expected to experience a slowdown in growth in 2024, influenced by various regulatory reforms and cost control measures[104] Risk Management - The company is committed to risk management through a cycle of risk identification, assessment, and continuous improvement to mitigate various risks[42] - The company acknowledges risks from policy changes in the pharmaceutical industry, which may impact sales and operational models, and is prepared to adjust strategies accordingly[161] - The fluctuation of raw material prices poses a significant risk to production costs, influenced by macroeconomic factors, natural disasters, and supply chain issues[165] - The company plans to strengthen market price monitoring and analysis, and implement strategic reserve purchasing to mitigate procurement costs[165] - Quality control risks arise from complex production processes and stringent regulatory standards, which could affect brand reputation[169] Corporate Governance - The company has established a system for insider information management to maintain disclosure fairness and compliance with regulations[179] - The total remuneration for the board of directors and senior management during the reporting period amounts to 1,877,720 yuan[184] - The company has a transparent information disclosure system to ensure all shareholders receive timely and accurate information[178] - The board of directors held three meetings during the year, with all members present at each meeting[192] - The audit committee convened five meetings during the reporting period, reviewing key financial reports and internal control evaluations[194][195] Employee Management - The company has a total of 1,266 employees, with 1,260 in major subsidiaries and 6 in the parent company[197] - The employee composition includes 589 production personnel, 141 sales personnel, 256 technical personnel, 62 financial personnel, and 218 administrative personnel[197] - The company has established a salary policy that links employee remuneration to company and individual performance, with a focus on industry salary benchmarks[198] - The company plans to optimize its salary system based on operational results and market conditions to enhance employee benefits[198]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 479,926,834.64, a decrease of 16.47% compared to CNY 574,528,830.84 in the same period last year[6] - Net profit attributable to shareholders was CNY 14,994,496.83, down 37.38% from CNY 23,944,713.73 year-on-year[6] - Total revenue for Q1 2025 was CNY 479,926,834.64, a decrease of 16.5% compared to CNY 574,528,830.84 in Q1 2024[22] - Operating profit for Q1 2025 was CNY 20,881,969.61, a decline of 34.3% compared to CNY 31,746,214.60 in Q1 2024[22] - The net profit for Q1 2025 was 15,717,573.30, a decrease of 37.4% compared to 25,123,136.63 in Q1 2024[23] - The company reported a total comprehensive income of 11,347,415.04 for Q1 2025, down 55.2% from 25,346,836.31 in Q1 2024[23] Cash Flow - The net cash flow from operating activities was negative at CNY -28,774,798.16, a decline of 167.22% compared to CNY 42,806,771.33 in the previous year[6] - The total revenue from operating activities in Q1 2025 was 392,984,135.62, down 23.4% from 512,993,663.80 in Q1 2024[26] - The net cash flow from operating activities for Q1 2025 was -28,774,798.16, compared to 42,806,771.33 in Q1 2024, indicating a significant decline[26] - The company incurred a cash outflow of 421,758,933.78 from operating activities in Q1 2025, compared to 470,186,892.47 in Q1 2024[26] - The net cash flow from financing activities for Q1 2025 was 37,211,883.85, a significant increase from 1,092,398.13 in Q1 2024[27] - The cash inflow from investment activities was -12,618,745.39 for Q1 2025, compared to -2,248,081.46 in Q1 2024, indicating increased cash outflow[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,122,566,299.08, a slight increase of 0.22% from CNY 3,115,812,628.78 at the end of the previous year[6] - Total assets as of March 31, 2025, amounted to CNY 3,122,566,299.08, compared to CNY 3,115,812,628.78 at the end of 2024[19] - Total liabilities decreased to CNY 672,411,521.45 as of March 31, 2025, from CNY 689,005,266.19 at the end of 2024[19] - Shareholders' equity attributable to the parent company increased by 0.45% to CNY 2,373,662,839.07 from CNY 2,363,038,500.50 at the end of the previous year[6] - Shareholders' equity increased to CNY 2,450,154,777.63 as of March 31, 2025, from CNY 2,426,807,362.59 at the end of 2024[19] Research and Development - Research and development expenses decreased by 14.55%, indicating a reduction in R&D investment compared to the previous year[7] - Research and development expenses for Q1 2025 were CNY 7,656,280.53, down from CNY 8,960,100.75 in Q1 2024[22] Other Financial Metrics - Basic and diluted earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 in the same period last year[6] - Basic earnings per share for Q1 2025 were 0.03, a decrease from 0.04 in Q1 2024[23] - The company reported a net impairment loss of CNY 3,910,182.42 in Q1 2025, compared to a gain of CNY 90,360.00 in Q1 2024[22] - The company reported a decrease in other comprehensive income, with a net amount of -4,370,158.26 for Q1 2025 compared to 223,699.68 in Q1 2024[23] Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[15] Government Subsidies - The company received government subsidies amounting to CNY 281,045.50 during the reporting period[8] Prepayments and Contract Liabilities - The company reported a significant increase in prepayments by 39.57%, primarily due to advance payments for Chinese medicinal materials[7] - Contract liabilities rose by 59.92%, attributed to the receipt of advance payments for goods[7]

关于上海神奇制药投资管理股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZA12008 号 上海神奇制药投资管理股份有限公司 上海神奇制药投资管理股份有限公司全体股东： 非经营性资金占用及其他关联资金 往来情况的专项报告 2024 年 12 月 31 日 我们审计了上海神奇制药投资管理股份有限公司股份有限公司 （以下简称"神奇制药公司"）2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表、2024 年度合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表和相 关财务报表附注，并于 2025 年 4 月 25 日出具了报告号为信会师报字 （2025）第 ZA12010 号的无保留意见审计报告。 神奇制药公司管理层根据中国证券监督管理委员会《上市公司监 管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监 会公告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南 第 2 号——业务办理》的相关规定编制了后附的 2024 年度非经营性 资金占用及其他关联资金往来情况汇总表（以下简称"汇总表" ...

| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2025-003 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 上海神奇制药投资管理股份有限公司 关于控股股东部分股票解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公司"） 的控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"）持有公司 90,661,620 股，占公司总股本 16.98%；本次解除质押后，神奇控股累计质押股 份 45,300,000 股，占公司总股份数 8.48%，占其持有公司股份 49.97%。 神奇控股及其控股公司贵州迈吉斯投资管理有限公司（以下简称"迈吉 斯"）合计持有公司 178,663,566 股，占公司总股本 33.45%；累计质押股份 111,669,000 股，占公司总股份数 20.91%，占其合计 ...